<?xml version="1.0" encoding="UTF-8"?>
<p>As these tools develop, we are likely to improve PD risk prediction in the general population, particularly when combined with pre-motor measures such as changes in olfaction and sleep, other measures including imaging, and, likely, biological markers. However, currently patients present to clinic with early PD and our challenge is to make an accurate diagnosis, to predict the future disease course and to modulate disease progress. The integration of clinical data with genetics is key to developing these approaches, with some progress already made in this regard [
 <xref rid="ref014" ref-type="bibr">14</xref>]. It is also likely that collaboration with industry and with large investigator led cohort studies will be central to success, and this has been a central theme of the last three IPDGC meetings.
</p>
